From in silico target prediction to multi-target drug design: current databases, methods and applications.
暂无分享,去创建一个
Andreas Bender | Meir Glick | Alexios Koutsoukas | Johannes Kirchmair | Jeremy L Jenkins | Peter J Bond | Robert C Glen | Benjamin Simms | Alan V Whitmore | Steven Zimmer | Malcolm P Young | R. Glen | A. Bender | J. Jenkins | M. Glick | Alexios Koutsoukas | Benjamin Simms | M. Young | P. Bond | J. Kirchmair | Alan Whitmore | Steven Zimmer | Meir Glick
[1] J. Jenkins,et al. Prediction of Biological Targets for Compounds Using Multiple‐Category Bayesian Models Trained on Chemogenomics Databases. , 2006 .
[2] C. Wermuth,et al. Multitargeted drugs: the end of the "one-target-one-disease" philosophy? , 2004, Drug discovery today.
[3] Jordi Mestres,et al. SHED: Shannon Entropy Descriptors from Topological Feature Distributions , 2006, J. Chem. Inf. Model..
[4] P. Bork,et al. A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.
[5] K. Fidelis,et al. Interaction Model Based on Local Protein Substructures Generalizes to the Entire Structural Enzyme‐Ligand Space. , 2009 .
[6] V. Poroikov,et al. Top 200 Medicines: Can New Actions be Discovered Through Computer-aided Prediction? , 2001, SAR and QSAR in environmental research.
[7] Zhe Shi,et al. Computer Aided Multi-target Drug Design, Multi-target Virtual Screening , 2010 .
[8] J. Dearden,et al. Design of new cognition enhancers: from computer prediction to synthesis and biological evaluation. , 2004, Journal of medicinal chemistry.
[9] C. E. Peishoff,et al. A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.
[10] Andreas Bender,et al. Ligand-Target Prediction Using Winnow and Naive Bayesian Algorithms and the Implications of Overall Performance Statistics , 2008, J. Chem. Inf. Model..
[11] J. Lamerdin,et al. Identifying off-target effects and hidden phenotypes of drugs in human cells , 2006, Nature chemical biology.
[12] Christophe Chipot,et al. Free Energy Calculations in Biological Systems. How Useful Are They in Practice , 2006 .
[13] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[14] Judith M. Rollinger,et al. Accessing target information by virtual parallel screening—The impact on natural product research , 2009 .
[15] Xin Wen,et al. BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..
[16] Xiaomin Luo,et al. PDTD: a web-accessible protein database for drug target identification , 2008, BMC Bioinformatics.
[17] Didier Rognan,et al. In silico-guided target identification of a scaffold-focused library: 1,3,5-triazepan-2,6-diones as novel phospholipase A2 inhibitors. , 2006, Journal of medicinal chemistry.
[18] R. Glen,et al. Molecular similarity: a key technique in molecular informatics. , 2004, Organic & biomolecular chemistry.
[19] J. Mestres,et al. A ligand-based approach to mining the chemogenomic space of drugs. , 2008, Combinatorial chemistry & high throughput screening.
[20] Simon K. Mencher,et al. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue) , 2005, BMC clinical pharmacology.
[21] A. Fliri,et al. Biological spectra analysis: Linking biological activity profiles to molecular structure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[22] K. Chou,et al. Predicting Drug-Target Interaction Networks Based on Functional Groups and Biological Features , 2010, PloS one.
[23] Didier Rognan,et al. Structure‐Based Approaches to Target Fishing and Ligand Profiling , 2010, Molecular informatics.
[24] Richard M. Jackson,et al. ReverseScreen3D: A Structure-Based Ligand Matching Method To Identify Protein Targets , 2011, J. Chem. Inf. Model..
[25] Camille G Wermuth,et al. Selective optimization of side activities: the SOSA approach. , 2006, Drug discovery today.
[26] H. Kubinyi. Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.
[27] J. Berg,et al. Molecular dynamics simulations of biomolecules , 2002, Nature Structural Biology.
[28] Edda Klipp,et al. Biochemical network-based drug-target prediction. , 2010, Current opinion in biotechnology.
[29] R. Morphy. Selectively nonselective kinase inhibition: striking the right balance. , 2010, Journal of medicinal chemistry.
[30] John A. Tallarico,et al. Use of ligand based models for protein domains to predict novel molecular targets and applications to triage affinity chromatography data. , 2009, Journal of proteome research.
[31] David L. Mobley,et al. Chapter 4 Alchemical Free Energy Calculations: Ready for Prime Time? , 2007 .
[32] Kai Huang,et al. PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach , 2010, Nucleic Acids Res..
[33] A. Fliri,et al. Analysis of drug-induced effect patterns to link structure and side effects of medicines , 2005, Nature chemical biology.
[34] Vladimir Poroikov,et al. QSAR Modelling of Rat Acute Toxicity on the Basis of PASS Prediction , 2011, Molecular informatics.
[35] Y. Martin,et al. Do structurally similar molecules have similar biological activity? , 2002, Journal of medicinal chemistry.
[36] Petra Schneider,et al. Self-organizing molecular fingerprints: a ligand-based view on drug-like chemical space and off-target prediction. , 2009, Future medicinal chemistry.
[37] Daniela Schuster,et al. 3D pharmacophores as tools for activity profiling. , 2010, Drug discovery today. Technologies.
[38] Andreas Bender,et al. Databases: Compound bioactivities go public , 2010 .
[39] A. Bender,et al. Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.
[40] Andreas Bender,et al. Molecular Similarity Searching Using Atom Environments, Information-Based Feature Selection, and a Naïve Bayesian Classifier , 2004, J. Chem. Inf. Model..
[41] Péter Csermely,et al. The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.
[42] Jean-Loup Faulon,et al. Genome scale enzyme–metabolite and drug–target interaction predictions using the signature molecular descriptor , 2008 .
[43] Y.Z. Chen,et al. Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.
[44] Peter G. Schultz,et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen , 2008, Proceedings of the National Academy of Sciences.
[45] E. Fischer. Einfluss der Configuration auf die Wirkung der Enzyme , 1894 .
[46] Andreas Bender,et al. Computational methods to support high-content screening: from compound selection and data analysis to postulating target hypotheses , 2009, Expert opinion on drug discovery.
[47] Yanli Wang,et al. PubChem: a public information system for analyzing bioactivities of small molecules , 2009, Nucleic Acids Res..
[48] Andreas Bender,et al. Understanding False Positives in Reporter Gene Assays: in Silico Chemogenomics Approaches To Prioritize Cell-Based HTS Data , 2007, J. Chem. Inf. Model..
[49] Andreas Bender,et al. How Similar Are Similarity Searching Methods? A Principal Component Analysis of Molecular Descriptor Space , 2009, J. Chem. Inf. Model..
[50] John A. Tallarico,et al. Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds , 2009, Nature Reviews Drug Discovery.
[51] Dariusz Plewczynski,et al. Target specific compound identification using a support vector machine. , 2007, Combinatorial chemistry & high throughput screening.
[52] Gerard J. P. van Westen,et al. Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets , 2011 .
[53] Andreas Bender,et al. Flexible 3D pharmacophores as descriptors of dynamic biological space. , 2007, Journal of molecular graphics & modelling.
[54] J. Epplen,et al. Indirect gene diagnoses for complex (multifactorial) diseases--a review. , 1995, Gene.
[55] Andreas Bender,et al. "Bayes Affinity Fingerprints" Improve Retrieval Rates in Virtual Screening and Define Orthogonal Bioactivity Space: When Are Multitarget Drugs a Feasible Concept? , 2006, J. Chem. Inf. Model..
[56] Raúl Toral,et al. RED: A Set of Molecular Descriptors Based on Re'nyi Entropy , 2009, J. Chem. Inf. Model..
[57] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[58] Roman A Zubarev,et al. Drug target identification from protein dynamics using quantitative pathway analysis. , 2011, Journal of proteome research.
[59] David S. Wishart,et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..
[60] Thierry Langer,et al. Parallel Screening and Activity Profiling with HIV Protease Inhibitor Pharmacophore Models , 2007, J. Chem. Inf. Model..
[61] Shigeyuki Yokoyama,et al. In silico functional profiling of small molecules and its applications. , 2008, Journal of medicinal chemistry.
[62] Y. Z. Chen,et al. Database of traditional Chinese medicine and its application to studies of mechanism and to prescription validation , 2006, British journal of pharmacology.
[63] Stefan H. E. Kaufmann,et al. Paul Ehrlich: founder of chemotherapy , 2008, Nature Reviews Drug Discovery.
[64] Jordi Mestres,et al. Computational chemogenomics approaches to systematic knowledge-based drug discovery. , 2004, Current opinion in drug discovery & development.
[65] Bernhard Kuster,et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.
[66] Vladimir Poroikov,et al. Multi-targeted natural products evaluation based on biological activity prediction with PASS. , 2010, Current pharmaceutical design.
[67] Thierry Langer,et al. In silico Target Fishing for Rationalized Ligand Discovery Exemplified on Constituents of Ruta graveolens , 2008, Planta medica.
[68] A. Bender,et al. In silico target fishing: Predicting biological targets from chemical structure , 2006 .
[69] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[70] Michael T. M. Emmerich,et al. A novel chemogenomics analysis of G protein-coupled receptors (GPCRs) and their ligands: a potential strategy for receptor de-orphanization , 2010, BMC Bioinformatics.
[71] Yi Wang,et al. In silico search of putative adverse drug reaction related proteins as a potential tool for facilitating drug adverse effect prediction. , 2006, Toxicology letters.
[72] Philip E. Bourne,et al. PROMISCUOUS: a database for network-based drug-repositioning , 2010, Nucleic Acids Res..
[73] Richard Morphy,et al. Designed Multiple Ligands. An Emerging Drug Discovery Paradigm , 2006 .
[74] D. Horvath,et al. G-protein-coupled receptor affinity prediction based on the use of a profiling dataset: QSAR design, synthesis, and experimental validation. , 2005, Journal of medicinal chemistry.
[75] Adriaan P. IJzerman,et al. Substructure Mining of GPCR Ligands Reveals Activity-Class Specific Functional Groups in an Unbiased Manner , 2009, J. Chem. Inf. Model..
[76] A. Hopkins. Network pharmacology , 2007, Nature Biotechnology.
[77] Thierry Langer,et al. Development and validation of an in silico P450 profiler based on pharmacophore models. , 2006, Current drug discovery technologies.
[78] Jürgen Bajorath,et al. Combining Horizontal and Vertical Substructure Relationships in Scaffold Hierarchies for Activity Prediction , 2011, J. Chem. Inf. Model..
[79] T. Klabunde,et al. GPCR Antitarget Modeling: Pharmacophore Models for Biogenic Amine Binding GPCRs to Avoid GPCR‐Mediated Side Effects , 2005, Chembiochem : a European journal of chemical biology.
[80] Xiaobo Zhou,et al. Predicting enzyme targets for cancer drugs by profiling human Metabolic reactions in NCI-60 cell lines , 2010, BMC Bioinformatics.
[81] L. Meijer,et al. Inverse in silico screening for identification of kinase inhibitor targets. , 2007, Chemistry & biology.
[82] John A. Tallarico,et al. Integrating high-content screening and ligand-target prediction to identify mechanism of action. , 2008, Nature chemical biology.
[83] Woody Sherman,et al. Large-Scale Systematic Analysis of 2D Fingerprint Methods and Parameters to Improve Virtual Screening Enrichments , 2010, J. Chem. Inf. Model..
[84] J. A. Bush,et al. Method for relating the structure and properties of chemical compounds , 1974, Nature.
[85] C. Mattingly,et al. The Comparative Toxicogenomics Database (CTD). , 2003, Environmental health perspectives.
[86] D. Barlow,et al. In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. , 2010, Bioorganic & medicinal chemistry.
[87] George Karypis,et al. Target Fishing for Chemical Compounds Using Target-Ligand Activity Data and Ranking Based Methods , 2009, J. Chem. Inf. Model..
[88] Mark A. Ragan,et al. A Semantic Web Ontology for Small Molecules and Their Biological Targets , 2010, J. Chem. Inf. Model..
[89] V. Poroikov,et al. PASS: identification of probable targets and mechanisms of toxicity , 2007, SAR and QSAR in environmental research.
[90] Ariel Fernández,et al. Turning promiscuous kinase inhibitors into safer drugs. , 2008, Trends in biotechnology.
[91] Martin Serrano,et al. Nucleic Acids Research Advance Access published October 18, 2007 ChemBank: a small-molecule screening and , 2007 .
[92] Shiwen Zhao,et al. Network-Based Relating Pharmacological and Genomic Spaces for Drug Target Identification , 2010, PloS one.
[93] J. Mestres,et al. In Silico Receptorome Screening of Antipsychotic Drugs , 2010, Molecular informatics.
[94] Janet M Thornton,et al. Ligand selectivity and competition between enzymes in silico , 2004, Nature Biotechnology.
[95] A. Bender,et al. Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data , 2007, ChemMedChem.
[96] P. Marks,et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.
[97] R. Solé,et al. The topology of drug-target interaction networks: implicit dependence on drug properties and target families. , 2009, Molecular bioSystems.
[98] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[99] Yoshihiro Yamanishi,et al. Supervised prediction of drug–target interactions using bipartite local models , 2009, Bioinform..
[100] Michael J. Keiser,et al. Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs. , 2010, Journal of medicinal chemistry.
[101] T. Lundstedt,et al. Development of proteo-chemometrics: a novel technology for the analysis of drug-receptor interactions. , 2001, Biochimica et biophysica acta.
[102] Z. Deng,et al. Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. , 2006, Journal of medicinal chemistry.
[103] O. Westphal,et al. Paul Ehrlich--in search of the magic bullet. , 2004, Microbes and infection.
[104] Thierry Langer,et al. Parallel Screening: A Novel Concept in Pharmacophore Modeling and Virtual Screening , 2006, J. Chem. Inf. Model..
[105] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[106] T. Pruett. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America , 2010 .
[107] Michael A. King,et al. The configurational dependence of binding free energies: A Poisson–Boltzmann study of Neuraminidase inhibitors , 2001, J. Comput. Aided Mol. Des..
[108] Anthony J Williams,et al. Public chemical compound databases. , 2008, Current opinion in drug discovery & development.
[109] Bryan L Roth,et al. Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. , 2004, Pharmacology & therapeutics.
[110] Didier Rognan,et al. Comparative evaluation of eight docking tools for docking and virtual screening accuracy , 2004, Proteins.
[111] André Schrattenholz,et al. Systems biology approaches and tools for analysis of interactomes and multi-target drugs. , 2010, Methods in molecular biology.
[112] Oliver Ebenhöh,et al. Ground State Robustness as an Evolutionary Design Principle in Signaling Networks , 2009, PloS one.
[113] Andreas Bender,et al. How similar are those molecules after all? Use two descriptors and you will have three different answers , 2010, Expert opinion on drug discovery.
[114] Peter A. Kollman,et al. FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA , 1993 .
[115] Y. Z. Chen,et al. Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach. , 2001, Journal of molecular graphics & modelling.
[116] Robert B. Russell,et al. SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..
[117] Jordi Mestres,et al. A General Analysis of Field-Based Molecular Similarity Indices , 2002 .
[118] M. Yoshida,et al. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. , 1993, The Journal of biological chemistry.
[119] Richard Morphy,et al. Designing multiple ligands - medicinal chemistry strategies and challenges. , 2009, Current pharmaceutical design.
[120] Bin Chen,et al. Chem2Bio2RDF: a semantic framework for linking and data mining chemogenomic and systems chemical biology data , 2010, BMC Bioinformatics.
[121] S. Giordano,et al. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. , 2008, Current medicinal chemistry.
[122] Mona Singh,et al. Toward the dynamic interactome: it's about time , 2010, Briefings Bioinform..
[123] David S. Wishart,et al. T3DB: a comprehensively annotated database of common toxins and their targets , 2009, Nucleic Acids Res..
[124] Choong Yong Ung,et al. Can an in silico Drug‐Target Search Method Be Used to Probe Potential Mechanism of Medicinal Plant Ingredients? , 2003 .
[125] Andreas Bender,et al. “Plate Cherry Picking”: A Novel Semi-Sequential Screening Paradigm for Cheaper, Faster, Information-Rich Compound Selection , 2007, Journal of biomolecular screening.
[126] Boon Chuan Low,et al. In-Silico Approaches to Multi-target Drug Discovery , 2010, Pharmaceutical Research.
[127] Lei Chen,et al. Prediction of interactiveness between small molecules and enzymes by combining gene ontology and compound similarity , 2009, J. Comput. Chem..
[128] Richard Morphy,et al. From magic bullets to designed multiple ligands. , 2004, Drug discovery today.
[129] P. Clemons,et al. Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint. , 2007, Combinatorial chemistry & high throughput screening.
[130] Thierry Langer,et al. LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..
[131] Gerald M. Maggiora,et al. On Outliers and Activity Cliffs-Why QSAR Often Disappoints , 2006, J. Chem. Inf. Model..
[132] Daniela Schuster,et al. Predicting cyclooxygenase inhibition by three-dimensional pharmacophoric profiling. Part II: Identification of enzyme inhibitors from Prasaplai, a Thai traditional medicine , 2011, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[133] José D Faraldo-Gómez,et al. Molecular Mechanism of Selective Recruitment of Syk Kinases by the Membrane Antigen-Receptor Complex* , 2011, The Journal of Biological Chemistry.
[134] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[135] E. Jacoby,et al. Chemogenomic strategies to expand the bioactive chemical space. , 2009, Current medicinal chemistry.
[136] J. Olivero-Verbel,et al. Theoretical targets for TCDD: a bioinformatics approach. , 2010, Chemosphere.
[137] C. Harris,et al. Chemogenomics: structuring the drug discovery process to gene families. , 2006, Drug discovery today.
[138] David Selwood,et al. Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala , 2005, Molecular Cancer Therapeutics.
[139] Y. Shoenfeld,et al. Antiinflammatory and immunomodulatory properties of statins , 2002, Immunologic research.
[140] Roger A. Sayle,et al. So you think you understand tautomerism? , 2010, J. Comput. Aided Mol. Des..
[141] Xiaohua Ma,et al. Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.
[142] Jean-Philippe Vert,et al. Virtual screening of GPCRs: An in silico chemogenomics approach , 2008, BMC Bioinformatics.
[143] P. Bork,et al. Large‐scale prediction of drug–target relationships , 2008, FEBS letters.
[144] X. Chen,et al. TTD: Therapeutic Target Database , 2002, Nucleic Acids Res..
[145] Thomas Bäck,et al. Combining Aggregation with Pareto Optimization: A Case Study in Evolutionary Molecular Design , 2009, EMO.
[146] David M. Rocke,et al. Predicting ligand binding to proteins by affinity fingerprinting. , 1995, Chemistry & biology.
[147] Nathanael Weill,et al. Development and Validation of a Novel Protein-Ligand Fingerprint To Mine Chemogenomic Space: Application to G Protein-Coupled Receptors and Their Ligands , 2009, J. Chem. Inf. Model..
[148] Pekka Tiikkainen,et al. Critical Comparison of Virtual Screening Methods against the MUV Data Set , 2009, J. Chem. Inf. Model..
[149] Andreas Bender,et al. Fishing the target of antitubercular compounds: in silico target deconvolution model development and validation. , 2009, Journal of proteome research.
[150] Pei Zhou,et al. Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding , 2007, Proceedings of the National Academy of Sciences.
[151] José L. Medina-Franco,et al. Characterization of Activity Landscapes Using 2D and 3D Similarity Methods: Consensus Activity Cliffs , 2009, J. Chem. Inf. Model..
[152] John M. Barnard,et al. Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..
[153] M. Ashburner,et al. Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.
[154] V. Poroikov,et al. Computer-aided prediction for medicinal chemistry via the Internet , 2008, SAR and QSAR in environmental research.